Luseogliflozin

Luseogliflozin

Chemical structure of Luseogliflozin

Luseogliflozin is an oral antidiabetic drug belonging to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). It is used in the management of type 2 diabetes mellitus to improve glycemic control in adults.

Mechanism of Action

Luseogliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubule of the nephron in the kidney. This inhibition reduces the reabsorption of glucose from the glomerular filtrate back into the bloodstream, leading to increased urinary glucose excretion and a reduction in blood glucose levels.

Pharmacokinetics

Luseogliflozin is administered orally and is absorbed in the gastrointestinal tract. It has a high bioavailability and is metabolized primarily in the liver. The drug and its metabolites are excreted via the urine and feces.

Clinical Use

Luseogliflozin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to achieve better glycemic control.

Side Effects

Common side effects of Luseogliflozin include urinary tract infections, genital mycotic infections, and increased urination. It may also cause hypotension due to its diuretic effect. Rarely, it can lead to ketoacidosis and acute kidney injury.

Contraindications

Luseogliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should not be used in patients with a history of serious hypersensitivity to the drug.

Related pages

• Type 2 diabetes mellitus
• Sodium-glucose co-transporter 2 inhibitors
• Antidiabetic drugs